
Lundbeck could pay as much as $658 million for neurological disorder specialist Chelsea Therapeutics as the firm looks to shore …
Biopharma development firm Chelsea Therapeutics has announced a major corporate reorganisation. The move includes a significant reduction in headcount, the …
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion

